Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature

Giuseppina Gallucci; Alfredo Tartarone; Carlo Gabriele Tocchetti; Anna Maria Bochicchio; Mariarosa Coccaro; Alba Capobianco; Nicola Maurea; Giuseppina Improta; Angela Zupa; Michele Aieta

doi:10.2217/fon.12.162

Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature

Giuseppina Gallucci, Alfredo Tartarone, Carlo Gabriele Tocchetti, Anna Maria Bochicchio, Mariarosa Coccaro, Alba Capobianco, Nicola Maurea, Giuseppina Improta, Angela Zupa, Michele Aieta

Research output: Contribution to journal › Article › peer-review

Abstract

Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.

Original language	English
Pages (from-to)	127-133
Number of pages	7
Journal	Future Oncology
Volume	9
Issue number	1
DOIs	https://doi.org/10.2217/fon.12.162
Publication status	Published - Jan 2013

Keywords

preeclampsia
sunitinib
TKI-induced cardiotoxicity

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.12.162

Fingerprint Dive into the research topics of 'Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature'. Together they form a unique fingerprint.

Cite this

Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity : Two cases and review of the literature. / Gallucci, Giuseppina; Tartarone, Alfredo; Tocchetti, Carlo Gabriele; Bochicchio, Anna Maria; Coccaro, Mariarosa; Capobianco, Alba; Maurea, Nicola; Improta, Giuseppina; Zupa, Angela; Aieta, Michele.

In: Future Oncology, Vol. 9, No. 1, 01.2013, p. 127-133.

Research output: Contribution to journal › Article › peer-review

Gallucci, Giuseppina ; Tartarone, Alfredo ; Tocchetti, Carlo Gabriele ; Bochicchio, Anna Maria ; Coccaro, Mariarosa ; Capobianco, Alba ; Maurea, Nicola ; Improta, Giuseppina ; Zupa, Angela ; Aieta, Michele. / Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity : Two cases and review of the literature. In: Future Oncology. 2013 ; Vol. 9, No. 1. pp. 127-133.

@article{77523213c7c240379bf26cc1beb2b2e8,

title = "Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: Two cases and review of the literature",

abstract = "Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.",

keywords = "preeclampsia, sunitinib, TKI-induced cardiotoxicity",

author = "Giuseppina Gallucci and Alfredo Tartarone and Tocchetti, {Carlo Gabriele} and Bochicchio, {Anna Maria} and Mariarosa Coccaro and Alba Capobianco and Nicola Maurea and Giuseppina Improta and Angela Zupa and Michele Aieta",

year = "2013",

month = jan,

doi = "10.2217/fon.12.162",

language = "English",

volume = "9",

pages = "127--133",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity

T2 - Two cases and review of the literature

AU - Gallucci, Giuseppina

AU - Tartarone, Alfredo

AU - Tocchetti, Carlo Gabriele

AU - Bochicchio, Anna Maria

AU - Coccaro, Mariarosa

AU - Capobianco, Alba

AU - Maurea, Nicola

AU - Improta, Giuseppina

AU - Zupa, Angela

AU - Aieta, Michele

PY - 2013/1

Y1 - 2013/1

N2 - Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.

AB - Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.

KW - preeclampsia

KW - sunitinib

KW - TKI-induced cardiotoxicity

UR - http://www.scopus.com/inward/record.url?scp=84871450791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871450791&partnerID=8YFLogxK

U2 - 10.2217/fon.12.162

DO - 10.2217/fon.12.162

M3 - Article

C2 - 23252570

AN - SCOPUS:84871450791

VL - 9

SP - 127

EP - 133

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1

ER -